Entrectinib as Treatment for NTRK-Positive Solid Tumors

(6:51)

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC

(4:27)

Entrectinib in patients with solid tumors and brain metastases

(1:31)

Considering Available Data for Entrectinib

(4:16)

Dr. Drilon on Entrectinib in Patients With Advanced Solid Tumors

(1:28)

ROS1 Treatment Options: Crizotinib and Entrectinib - 2022 Program: Targeted Therapies Forum

(7:7)

Safety analysis of entrectinib for NTRK fusion tumours

(9:34)

Entrectinib is an investigational therapy designed to target cancers

(3:18)

Entrectinib–Selective ROS Inhibition

(4:45)

Progress in Treating Advanced Thyroid Cancers with Dr. Wirth | Targeted Therapy Insights

(1:2:47)

Understanding NSCLC Treatments for Less Common Mutations: ALK, BRAF, ROS1, HER2, MET

(5:41)

All About Radiation Oncology - 09/17/24 - Lung Cancer Living Room™

(42:49)

New Cancer Treatment Advancements: Antibody-Drug Conjugates | Precision Oncology

(34:25)

Evolving Landscape of Targeted Therapies | Dr. Lizza Hendriks

(25:6)

ALK/ROS positive Lung cancer | Brain metastases | Leptomeningeal metastases | Dr. Chandrakanth M V

(10:22)

Macrocyclic TKIs in Treatment-Naïve and Pretreated Fusion-Positive NSCLC and Other Tumors

(28:43)

2023 Best of Lung: Targeted Therapies in Lung Cancer

(30:32)

Managing ROS1 fusion-positive NSCLC in Europe and the USA | Panel discussion

(37:34)

Pediatric TRK Fusion-Positive Cancer: Optimizing Care With TRK Inhibitors

(28:47)

Dr. Drilon on Entrectinib in Patients With ROS1-Positive NSCLC

(2:12)

Entrectinib–A Multitargeted TKI

(6:39)

Evaluating Next Steps for Entrectinib in ROS1-Positive NSCLC

(40)

Analyzing the Data for Entrectinib in ROS1 TKI-Naive Patients With NSCLC

(1:22)

Treatment for NTRK+ NSCLC: Larotrectinib \u0026 Entrectinib - 2022 Program: Targeted Therapies Forum

(8:54)

Dr. Desai on Phase I Study of Entrectinib in Solid Tumors

(59)

Dr. Levy on the Efficacy of Crizotinib Versus Entrectinib in ROS1+ Lung Cancer

(2:3)

Dr. Levy on Entrectinib in Oncogene-Driven NSCLC

(1:34)

Dr. Patel on the Safety Profile of Entrectinib in NTRK+ Solid Tumors

(1:25)

The Significance of Results for Entrectinib in ROS1+ NSCLC

(47)